Skip to main content
Transgene logo

Transgene — Investor Relations & Filings

Ticker · TNG ISIN · FR0005175080 LEI · 969500PDJW8N0FSGGK69 PA Professional, scientific and technical activities
Open in API
Filings indexed 796 across all filing types
Latest filing 2014-04-28 Regulatory Filings
Country FR France
Listing PA TNG

About Transgene

https://www.transgene.fr/en/

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Transgene announcing that Novartis did not exercise its option on the drug candidate TG4010. It details the company's plans to proceed with Phase 3 trials and actively seek a new partner. It also includes details about an upcoming conference call. This type of announcement, which communicates a significant business development (loss of option, continuation of development, search for partnership) via a press release format, is typically classified as an Earnings Release (ER) if it relates to periodic results, or a Regulatory Filing (RNS) if it's a general corporate update. Since this is a specific, material business event announcement (not a full financial report like 10-K or IR, nor a management discussion like MDA), and it is not explicitly about dividends, capital changes, or director dealings, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate event disclosure, or potentially an Earnings Release (ER) if it were tied to a quarterly period, but the focus here is on a partnership/development update. Given the options, and that it's a formal announcement of a material event, RNS is the most appropriate fallback for a non-standard, material corporate update. However, since it discusses the continuation of clinical trials and future plans, it is a key piece of investor information. Given the structure and content (announcement of a major business decision and scheduling a call), it strongly resembles an Earnings Release (ER) which often includes operational updates alongside financial context, or a general corporate update. Since it is not a full financial report, and the primary focus is a business development update, RNS is the safest general classification for material, non-standard announcements. Upon review, ER is often used for press releases accompanying results, but this is a specific operational/partnership update. I will classify it as RNS as a material corporate announcement that doesn't fit other specific categories like CAP, TAR, or DIV.
2014-04-28 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 1% confidence The document is explicitly titled "Transgene Reports First Quarter 2014 Financial Results" and contains key financial metrics (Operating revenue, Cash position) comparing Q1 2014 to Q1 2013. This structure—a summary announcement of financial performance for a period shorter than a full year—is characteristic of an Earnings Release (ER). It is not the comprehensive report itself (which would be an IR), nor is it a transcript (CT) or a full annual report (10-K). The document provides the highlights and key figures immediately, fitting the definition of an Earnings Release. Q1 2014
2014-04-22 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial update from Transgene for the period ending March 31, 2014. It contains substantive financial data, including operating income tables and cash flow analysis, rather than just an announcement of a report's availability. It qualifies as an Interim/Quarterly Report (IR) because it provides actual financial results for a period shorter than a full fiscal year. Q1 2014
2014-04-22 French
Communiqués de mise à disposition de documents / Modalités de mise à disposition document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is very short (638 characters) and its title is "Communiqué de mise à disposition du document de référence 2013" (Announcement of the availability of the 2013 reference document). The text explicitly states that the company has made available and filed its 2013 reference document (which includes the annual financial report, corporate governance report, and auditor fees communication) and directs the reader to the company website to consult it. This perfectly matches the definition of a Report Publication Announcement (RPA), as it is an announcement about the availability of other reports, rather than the reports themselves. It is not a full 10-K or AR.
2014-04-22 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 1% confidence The document is a comprehensive financial announcement from Transgene S.A. detailing its 2013 annual financial results, including a consolidated income statement, cash flow analysis, and detailed operational updates on R&D programs. While it mentions a conference call, the document itself contains the actual financial data and management commentary, distinguishing it from a mere announcement of a report (RPA). It is not a full 10-K (which is a specific US regulatory filing) but rather an annual earnings release/report for a French company, which fits the 'Earnings Release' (ER) category as it provides the initial announcement of yearly financial results and key highlights. FY 2013
2014-03-26 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 1% confidence The document is titled "Transgene Reports Fiscal Year 2013 Results and Provides Business Update" and contains detailed consolidated financial statements (Income Statement and Balance Sheet summary) for the fiscal year ended December 31, 2013. It explicitly mentions that the financial statements were approved by the Board and will be submitted for shareholder approval at the upcoming AGM. This structure—a press release summarizing annual financial performance, including key figures and tables, alongside a business update—is characteristic of an Earnings Release (ER) or a document accompanying the Annual Report. Since it provides the core financial results summary immediately, it fits the definition of an Earnings Release (ER) announcing the period's results. It is not the full 10-K, nor is it just a notice of publication (RPA). The presence of the full financial tables and the focus on the 'Fiscal Year 2013 Results' strongly points to ER. FY 2013
2014-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.